Related Experiment Video
Updated: May 1, 2026
13:47
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
Published on: June 23, 2011
19.0K
Development of universal antidotes to control aptamer activity
Sabah Oney1, Ruby T S Lam, Kristin M Bompiani
1Duke Translational Research Institute, Duke University Medical Center, Department of Surgery, University Program in Genetics and Genomics, Duke University, Durham, North Carolina, USA.
Nature Medicine
|October 6, 2009
Summary
Researchers developed universal antidote molecules to safely control aptamer therapeutics. These novel antidotes can counteract an entire class of aptamer drugs, enhancing patient safety and potentially reducing treatment costs.
Area of Science:
- Biotechnology
- Drug Development
- Molecular Biology
Background:
- Increasing medication use necessitates safer drug administration and reduced side effects.
- Developing specific antidotes for each therapeutic agent is challenging and costly.
Purpose of the Study:
- To develop universal antidote molecules capable of counteracting an entire class of aptamer-based therapeutics.
- To address the limitations of current antidote generation methods.
Main Methods:
- Exploited aptamers as the only free extracellular oligonucleotides in circulation.
- Designed protein- and polymer-based molecules to capture oligonucleotides.
- Tested antidote efficacy in vitro and in vivo.
Main Results:
- Demonstrated that universal antidotes can reverse aptamer activity in vitro.
- Confirmed that these molecules counteract aptamer activity in vivo.
- Established a method for controlling aptamer drug effects.
Conclusions:
- Universal aptamer antidotes offer a promising strategy for enhancing therapeutic safety.
- This approach could make aptamers a safer class of therapeutics.
- The development facilitates better control over drug activity and side effects.
